Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
19 11 2022
Historique:
received: 06 05 2022
accepted: 10 11 2022
revised: 08 11 2022
entrez: 19 11 2022
pubmed: 20 11 2022
medline: 23 11 2022
Statut: epublish

Résumé

Tuft cells are chemosensory epithelial cells in the respiratory tract and several other organs. Recent studies revealed tuft cell-like gene expression signatures in some pulmonary adenocarcinomas, squamous cell carcinomas (SQCC), small cell carcinomas (SCLC), and large cell neuroendocrine carcinomas (LCNEC). Identification of their similarities could inform shared druggable vulnerabilities. Clinicopathological features of tuft cell-like (tcl) subsets in various lung cancer histotypes were studied in two independent tumor cohorts using immunohistochemistry (n = 674 and 70). Findings were confirmed, and additional characteristics were explored using public datasets (RNA seq and immunohistochemical data) (n = 555). Drug susceptibilities of tuft cell-like SCLC cell lines were also investigated. By immunohistochemistry, 10-20% of SCLC and LCNEC, and approximately 2% of SQCC expressed POU2F3, the master regulator of tuft cells. These tuft cell-like tumors exhibited "lineage ambiguity" as they co-expressed NCAM1, a marker for neuroendocrine differentiation, and KRT5, a marker for squamous differentiation. In addition, tuft cell-like tumors co-expressed BCL2 and KIT, and tuft cell-like SCLC and LCNEC, but not SQCC, also highly expressed MYC. Data from public datasets confirmed these features and revealed that tuft cell-like SCLC and LCNEC co-clustered on hierarchical clustering. Furthermore, only tuft cell-like subsets among pulmonary cancers significantly expressed FOXI1, the master regulator of ionocytes, suggesting their bidirectional but immature differentiation status. Clinically, tuft cell-like SCLC and LCNEC had a similar prognosis. Experimentally, tuft cell-like SCLC cell lines were susceptible to PARP and BCL2 co-inhibition, indicating synergistic effects. Taken together, pulmonary tuft cell-like cancers maintain histotype-related clinicopathologic characteristics despite overlapping unique molecular features. From a therapeutic perspective, identification of tuft cell-like LCNECs might be crucial given their close kinship with tuft cell-like SCLC.

Identifiants

pubmed: 36402755
doi: 10.1038/s41419-022-05428-x
pii: 10.1038/s41419-022-05428-x
pmc: PMC9675833
doi:

Substances chimiques

Proto-Oncogene Proteins c-bcl-2 0
FOXI1 protein, human 0
Forkhead Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

979

Informations de copyright

© 2022. The Author(s).

Références

Clin Cancer Res. 2018 Jan 15;24(2):360-369
pubmed: 29118061
Cell. 1990 Nov 16;63(4):827-34
pubmed: 1699669
Cancer. 1977 Aug;40(2):707-15
pubmed: 196741
J Thorac Oncol. 2020 Dec;15(12):1836-1843
pubmed: 32721553
Am J Surg Pathol. 1991 Jun;15(6):529-53
pubmed: 1709558
Cell Rep. 2020 Oct 20;33(3):108296
pubmed: 33086069
Cancer Cell. 2021 Nov 8;39(11):1479-1496.e18
pubmed: 34653364
Immunity. 2020 Apr 14;52(4):683-699.e11
pubmed: 32294408
Nature. 2016 Jan 14;529(7585):226-30
pubmed: 26762460
PLoS One. 2017 Dec 7;12(12):e0189340
pubmed: 29216297
Cancer Cell. 2021 Mar 8;39(3):346-360.e7
pubmed: 33482121
Nat Commun. 2021 Jul 1;12(1):4055
pubmed: 34210965
J Thorac Oncol. 2022 Sep;17(9):1109-1121
pubmed: 35760287
Nat Rev Immunol. 2019 Sep;19(9):584-593
pubmed: 31114038
Nature. 2018 Jul;559(7715):622-626
pubmed: 30022162
Neuro Oncol. 2020 Dec 18;22(12):1840-1850
pubmed: 32347934
J Clin Oncol. 2018 Aug 10;36(23):2386-2394
pubmed: 29906251
Clin Cancer Res. 2017 Jan 15;23(2):523-535
pubmed: 27440269
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Science. 2016 Mar 18;351(6279):1329-33
pubmed: 26847546
J Thorac Oncol. 2020 May;15(5):843-859
pubmed: 32004714
Sci Adv. 2021 Jan 29;7(5):
pubmed: 33514539
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
Br J Cancer. 2021 Mar;124(5):857-859
pubmed: 33328609
Genes Dev. 2018 Jul 1;32(13-14):915-928
pubmed: 29945888
J Thorac Oncol. 2020 Dec;15(12):1823-1835
pubmed: 33011388
Nature. 2018 Aug;560(7718):377-381
pubmed: 30069046
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Ann Oncol. 2005 Nov;16(11):1811-6
pubmed: 16087693
Nat Commun. 2018 Jan 12;9(1):176
pubmed: 29330466
Nature. 2016 Jan 14;529(7585):221-5
pubmed: 26675736
J Thorac Oncol. 2022 Jan;17(1):141-153
pubmed: 34534680
J Thorac Oncol. 2021 Jun;16(6):1003-1016
pubmed: 33609752
Int J Mol Med. 2020 Feb;45(2):279-297
pubmed: 31894255
Jpn J Clin Oncol. 2019 Aug 1;49(8):703-707
pubmed: 31242303
Br J Cancer. 2021 Mar;124(5):951-962
pubmed: 33339894
J Thorac Oncol. 2021 Mar;16(3):464-476
pubmed: 33248321
Elife. 2022 Sep 21;11:
pubmed: 36129169
Nature. 2015 Aug 6;524(7563):47-53
pubmed: 26168399
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
Cancer Cell. 2020 Jul 13;38(1):60-78.e12
pubmed: 32473656
Virchows Arch. 2022 Apr;480(4):843-851
pubmed: 34988657
Oncogene. 2021 Apr;40(14):2483-2495
pubmed: 33686241
J Natl Cancer Inst. 2016 May 31;108(10):
pubmed: 27247353
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nature. 2012 Sep 27;489(7417):519-25
pubmed: 22960745
Immunol Lett. 2019 Jun;210:1-9
pubmed: 30904566
Nature. 2022 Jul;607(7917):169-175
pubmed: 35576971
Cell Chem Biol. 2022 Feb 17;29(2):202-214.e7
pubmed: 34329582
Nature. 2018 Jul;559(7715):627-631
pubmed: 30022164
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121979119
pubmed: 35259019
Eur Urol. 2020 Jul;78(1):63-74
pubmed: 32299640
Nature. 2018 Aug;560(7718):319-324
pubmed: 30069044
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341

Auteurs

Yosuke Yamada (Y)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. yyamada@kuhp.kyoto-u.ac.jp.
Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. yyamada@kuhp.kyoto-u.ac.jp.

Djeda Belharazem-Vitacolonnna (D)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Hanibal Bohnenberger (H)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Christel Weiß (C)

Department of Medical Statistics and Biomathematics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Naoko Matsui (N)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Mark Kriegsmann (M)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Katharina Kriegsmann (K)

Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.

Peter Sinn (P)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Katja Simon-Keller (K)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Gerhard Hamilton (G)

Institute for Pharmacology, Medical University of Vienna, Vienna, Austria.

Thomas Graeter (T)

Thoracic Surgery, Klinik Löwenstein, Löwenstein, Germany.

Gerhard Preissler (G)

Department of Thoracic Surgery, Klinik Schillerhöhe GmbH am Robert-Bosch-Krankenhaus, Stuttgart, Germany.

German Ott (G)

Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

Sebastian Schölch (S)

Department of Surgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany.
Junior Clinical Cooperation Unit Translational Surgical Oncology (A430), German Cancer Research Center (DKFZ), Heidelberg, Germany.
DKFZ Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany.

Naoki Nakajima (N)

Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Akihiko Yoshizawa (A)

Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Hironori Haga (H)

Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Hiroshi Date (H)

Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Roman K Thomas (RK)

Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany.
Institute of Pathology, University of Cologne, Cologne, Germany.
German Cancer Consortium (DKTK), partner site Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Iacopo Petrini (I)

Department of Translational Research and New Technologies in Medicine, University Hospital of Pisa, Pisa, Italy.

Giuseppe Giaccone (G)

Weill Cornell Medicine, Cornell University, New York, NY, USA.

Philipp Ströbel (P)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Alexander Marx (A)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH